

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/608,296	06/27/2003	Gail Isabel Reid Adam	524592003100	9001	
25225	7590 03/09/2006		EXAMINER		
MORRISON & FOERSTER LLP			SITTON, JEHANNE SOUAYA		
12531 HIGH I SUITE 100	BLUFF DRIVE		ART UNIT	PAPER NUMBER	
	CA 92130-2040		1634		
			DATE MAILED: 02/00/2004	c	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)				
Office Action Summary		10/608,29	16	ADAM ET AL.				
		Examiner		Art Unit				
		Jehanne S	S. Sitton	1634				
Period fo	The MAILING DATE of this communication Reply	ion appears on the	cover sheet with th	ne correspondence a	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL asions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communical operiod for reply is specified above, the maximum statutor re to reply within the set or extended period for reply will, the provision of the provision o	ING DATE OF TH 7 CFR 1.136(a). In no eve ation. ry period will apply and wi by statute, cause the appl	IIS COMMUNICAT ent, however, may a reply b II expire SIX (6) MONTHS i lication to become ABANDO	ION. be timely filed from the mailing date of this ONED (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) filed or	n 19 December 20	<i>005</i> .		·			
2a)□	This action is FINAL . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	on of Claims							
4)⊠	4)⊠ Claim(s) <u>1-30</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)⊠	Claim(s) 1-30 is/are rejected.							
7)	Claim(s) is/are objected to.							
8)□	Claim(s) are subject to restriction	and/or election re	equirement.					
Applicat	on Papers							
9)[The specification is objected to by the Ex	xaminer.						
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the	correction is require	ed if the drawing(s) is	objected to. See 37 (CFR 1.121(d).			
11)	The oath or declaration is objected to by	the Examiner. No	te the attached Off	fice Action or form P	PTO-152.			
Priority (ınder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International	•	` ''					
* 5	See the attached detailed Office action fo	or a list of the certif	fied copies not rece	eived.				
Attachmen	t(s)							
_	e of References Cited (PTO-892)		4) Interview Summ	nary (PTO-413)				
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-9		Paper No(s)/Ma	il Date	FO 450)			
	nation Disclosure Statement(s) (PTO-1449 or PTO r No(s)/Mail Date	0/SB/08)	i)					

Application/Control Number: 10/608,296 Page 2

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 3-4, 8, and 12-13 drawn to a method of diagnosing predisposition to fat deposition or leanness in a subject by determining the identify of the nucleotide at position 7328 of SEQ ID NO: 1, or a polymorphic variation in linkage disequilibrium thereof, classified in class 435, subclass 6.
- II. Claims 5-6, 8, and 14-15 drawn to a method of diagnosing predisposition to fat deposition or leanness in a subject by determining the identify of the nucleotide at position 9182 of SEQ ID NO: 1, or a polymorphic variation in linkage disequilibrium thereof, classified in class 435, subclass 6.
- III. Claim 17, drawn to a method of identifying a polymorphic variation associated with fat deposition proximal to an incident polymorphism wherein the first polymorphic variation is located at position 7328 of SEQ ID NO: 1, classified in class 435, subclass 6.
- IV. Claim 17, drawn to a method of identifying a polymorphic variation associated with fat deposition proximal to an incident polymorphism wherein the first polymorphic variation is located at position 9182 of SEQ ID NO: 1, classified in class 435, subclass 6.
- V. Claims 22-24, drawn to a method of diagnosing a predisposition to NIDDM by detecting a polymorphic variation in SEQ ID NO: 1, classified in class 435, subclass 6.

VI. Claims 25-30, drawn to a method of identifying a polymorphic variation associated with NIDDM proximal to an incident polymorphism in SEQ ID NO: 1, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

2. Claims 1-2, 7, and 9-11 link(s) inventions I and II. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 1-2, 7, and 9-10. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim(s) including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

3. Additionally, groups I and II named above are subject to further restriction with regard to claim 8. Applicant is required to further elect a specific SEQ ID NO or primer pair which is

Application/Control Number: 10/608,296

serious burden for the office.

Art Unit: 1634

directed to either of the elected polymorphisms. This is NOT an election of species. The nucleotide sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 USC 121 and 37 CFR 1.141. By statute, "[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions." 35 U.S.C. 121. Pursuant to this statute, the rules provide that "[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant... to elect that invention to which his claim shall be restricted." 37 CFR 1.142 (a). See also 37 CFR 1.141(a). It is noted that searching more than one of the claimed patentably distinct sequences represents a

Page 4

4. Claims 16, and 18-21 link(s) inventions III and IV. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 16 and 18-21. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are

Art Unit: 1634

governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim(s) including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

5. Groups I, II and V are patentably distinct from each other as they are drawn to methods of detecting structurally distinct polymorphic positions and are unobvious over one another.

Searching is not coextensive as the search for each polymorphism is distinct.

Groups III, IV, and VI patentably distinct from each other as they are drawn to methods of detecting structurally distinct polymorphic positions and are unobvious over one another.

Searching is not coextensive as the search for each polymorphism is distinct.

Groups I, II, &V are patentably distinct from groups III, IV, & VI as the groups involve different methods steps and identification of distinct polymorphisms. Methods of disease diagnosis (groups I, II, and V) and methods of identifying polymorphisms (groups III, IV, and VI) have different objectives and different functions, requiring different methods steps and parameters. Searching is not coextensive as art relating to methods of diagnosis would not necessarily provide any information regarding analysis of proximal polymorphisms to determine an association between different polymorphisms relative to each other, and vice versa.

Application/Control Number: 10/608,296 Page 6

Art Unit: 1634

6. Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

7. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-

Application/Control Number: 10/608,296 Page 7

Art Unit: 1634

0752. The examiner can normally be reached Monday-Thursday from 8:00 AM to 5:00 PM and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571) 272-0745. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Jehanne Sitton Primary Examiner

Art Unit 1634

3/3/06